Latigo Biotherapeutics (LTGO) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Latigo Biotherapeutics is the larger company by market cap ($1.03 billion vs $1.01 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LTGO | SVRA |
|---|---|---|
| Share price | $15.59 | $4.94 |
| Market cap | $1.03B | $1.01B |
| 1-day change | +5.38% | +2.17% |
| YTD return | — | -19.90% |
| 1-year return | — | +39.19% |
| 5-year return | — | +274.42% |
| EPS (TTM) | $-2.52 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.93 | $7.01 |
| 52-week low | $14.60 | $3.35 |
| Distance from 52-week high | -39.90% | -29.55% |
| Analyst consensus | none | none |
| Avg. price target upside | +235.26% | +124.11% |
| Average volume | 391.26K | 1.83M |
| Shares outstanding | 66.30M | 205.46M |
| Employees | 66 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
LTGO vs SVRA FAQ
Which is bigger, Latigo Biotherapeutics or Savara?
Latigo Biotherapeutics (LTGO) is larger, with a market capitalization of $1.03B compared with $1.01B for Savara (SVRA).
Are Latigo Biotherapeutics and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.